CBDV, or cannabidivarin, is a non-intoxicating cannabinoid that occurs naturally in certain types of Cannabis sativa. It is closely related to CBD, but with a slightly different chemical structure that gives it its own characteristics. Although it was first identified in the 1960s, interest in CBDV has increased in more recent years.
From what I have seen over time, there is growing interest in cannabinoids beyond well-known compounds such as CBD and THC. CBDV is one of those lesser-known compounds that is starting to receive more attention, both in research and in conversations around cannabinoid diversity.
I find it interesting how these minor cannabinoids are gradually reshaping the way we understand the cannabis plant. As more information becomes available, I have wanted to take a closer look at what makes CBDV different and why it matters.
Prefer watching over reading? This video covers the key points from the article:
Key takeaways
- CBDV (cannabidivarin) is a lesser-known phytocannabinoid naturally found in hemp, offering unique characteristics within the cannabinoid family.
- Unlike THC, CBDV is not associated with psychoactive effects, making it a focus for researchers and product developers exploring non-intoxicating compounds.
- CBDV’s distinct molecular structure sets it apart from other cannabinoids, prompting continued investigation into its chemical and receptor interactions.
- Ongoing exploration of CBDV contributes to a deeper scientific understanding of Cannabis sativa and its broader cannabinoid profile.
This article is provided for informational purposes only and does not relate to any of the products available in our online shop. For more information, please see our full disclaimer.
Understanding CBDV (cannabidivarin) and its origins
Cannabidivarin (CBDV) is a naturally occurring cannabinoid found in certain varieties of Cannabis sativa, particularly those with lower levels of THC. It was first identified in the 1960s and has since gained attention for its unique structure and non-intoxicating nature.
While CBDV is structurally similar to CBD, subtle differences in its chemical makeup have made it a subject of growing interest in cannabinoid research. These differences are part of what sets CBDV apart within the broader group of naturally occurring compounds found in the cannabis plant.
Defining CBDV in the context of Cannabis sativa
CBDV is a naturally occurring cannabinoid synthesised by Cannabis sativa. This plant species contains a complex mix of compounds, including cannabinoids, terpenoids and flavonoids. Cannabinoids are formed through their own metabolic pathway, in which geranyl diphosphate (GPP), a building block from the plant's isoprenoid pathway, is combined with a phenolic acid: olivetolic acid for CBD and THC, or divarinolic acid for CBDV.
CBDV emerges as one of the many phytocannabinoids produced under specific genetic and environmental conditions.
The botanical sources of CBDV
CBDV is predominantly obtained from Cannabis sativa strains selectively cultivated for their cannabinoid profiles. Agricultural practices aimed at enhancing specific phytochemical outputs play a significant role in the production of CBDV.
Observations suggest that the variation in CBDV concentrations is influenced both by the plant’s genetic characteristics and by environmental factors such as soil quality, climate and cultivation methods.
A 2022 study published in Plants (MDPI) by Kim et al. measured CBDV and other cannabinoids in five commercial cultivars and reported correlations between cannabinoid levels and the expression of biosynthetic genes, supporting the understanding of CBDV variability.
What is THC (tetrahydrocannabinol)?
Chemical structure and properties of CBDV
Looking into the CBDV chemical structure shows that it differs from other cannabinoids such as CBD and THC. Its distinct molecular makeup is important for understanding why it is non-intoxicating. This is notable for its potential relevance within ongoing scientific research.
Learning about cannabinoid biosynthesis in cannabis plants provides insight into how these compounds are formed. This knowledge supports the scientific exploration of CBDV’s biological interactions. The process is complex, and it explains how CBDV comes to have a shorter side chain than CBD.
CBDV’s non-psychoactive character makes it a subject of interest in scientific research. Unlike THC, CBDV does not produce euphoria or alteration of perception, which supports its investigation for different applications.
Based on my analysis of available studies, this distinct property positions CBDV as an area of continuing academic focus within cannabinoid science.
| Compound | Psychoactive property | Chemical structure |
|---|---|---|
| CBDV | Non-psychoactive | Propyl (three-carbon) side chain, shorter than in CBD and THC |
| CBD | Non-psychoactive | Pentyl (five-carbon) side chain; otherwise similar to CBDV |
| THC | Psychoactive | Pentyl (five-carbon) side chain; acts as a partial agonist at cannabinoid receptors |
Medical research and potential uses of CBDV
Scientific interest in cannabidivarin (CBDV) has grown in recent years, particularly concerning its study within neurological research contexts.
Researchers are investigating CBDV’s interaction with biological systems relevant to neurological studies, focusing on its non-intoxicating properties and the potential relevance of its chemical structure within the context of neurological research.
Influence of CBDV on neurological function
CBDV is not associated with psychoactive effects, which supports its study without concerns related to altered cognitive perception. Research has investigated its interactions with neurological pathways, examining its presence in studies related to nerve activity.
A paper published in Epilepsia (2022) reported a small, open-label phase 1 trial in five girls with Rett syndrome and drug-resistant epilepsy, which assessed the safety and tolerability of CBDV and changes in seizure frequency. Because the trial was small and had no control group, it highlights an area of scientific interest for future research rather than established effects, and further work is needed to understand its potential applications.
Autism and CBDV: investigating the connections
The connection between CBDV and autism spectrum conditions has attracted growing attention in the scientific community. Investigators are exploring whether CBDV affects neurological pathways involved in behavioural expression.
Early-stage animal and human studies, such as those reviewed in Pharmacology & Therapeutics (2021), have examined CBDV in autism-related research, with no definitive conclusions regarding its use.
CBDV in epilepsy research
CBDV’s non-psychoactive nature has led to its inclusion in studies investigating seizure-related mechanisms. Preclinical research has examined CBDV in seizure models to support scientific understanding of its interaction with neurological pathways, without the psychoactive impact associated with THC.
Clinical studies in humans, such as the small Rett syndrome trial described above, have begun to assess its potential, although findings remain at the investigative stage and require further validation before any conclusions can be drawn regarding clinical applications.
Which cannabinoids produce a psychoactive effect?
Exploring the potential side effects and safety profile of CBDV
I can see how important it is to understand the safety profile of CBDV. Cannabinoid research is now focusing on the side effects of cannabinoids such as CBDV.
Recent regulatory work shows why composition matters. A safety assessment report by the UK Food Standards Agency and Food Standards Scotland on a CBD isolate proposed as a novel food measured CBDV as a minor component across production batches and set a maximum level for it in the specification, but it did not evaluate the safety of CBDV on its own. This shows the need for strict quality control and a deep understanding of its effects.
As someone committed to responsible research, I believe it is important to carefully assess any observed effects of CBDV in relation to its areas of study. Evaluating observed properties alongside possible risks is essential for maintaining high standards of safety and quality.
Taking a detailed and open approach to assessing CBDV plays an important role in fostering trust with consumers and supporting confidence in the products offered.
Research into CBDV remains an evolving field. My focus continues to be directed towards the investigation of its side effect profile and the establishment of robust safety standards. Every phase, from laboratory studies to considerations around product formulation, must meet high expectations for safety and scientific integrity.
How are new cannabinoids being discovered and classified?
CBDV products and their availability
There has been growing interest in products featuring cannabidivarin (CBDV), driven by increasing consumer curiosity towards cannabinoid-based options. These products are now offered in various formats, often referred to as full-spectrum or broad-spectrum, indicating the differing profiles of cannabinoids present.
These formulations may combine CBDV with other naturally occurring cannabinoids such as cannabidiol (CBD). Full-spectrum products can also contain trace amounts of delta-9-tetrahydrocannabinol (THC), whereas broad-spectrum products are described as nearly THC-free.
Variations in cannabinoid profiles across different products highlight the importance of consistent manufacturing practices and clear, accurate labelling to support consumer confidence.
Among the available formats, tinctures containing CBDV are one option and are often described as adaptable and easy to use. The complexity of the cannabis plant presents both challenges and opportunities in product development.
As scientific understanding of CBDV advances, I anticipate that the market will continue to refine standards relating to product quality and cannabinoid composition.
Personal perspective
When I first became involved with cannabinoids, I rarely heard anyone mention CBDV. Even though researchers had identified it years earlier, it seemed to sit quietly in the background. As curiosity around the full complexity of the cannabis plant started growing, I began paying more attention to this particular compound and what sets it apart.
What keeps drawing me to CBDV is its distinct structure and how it interacts with the body: rather than binding strongly to the classic cannabinoid receptors, it acts on other targets, such as certain ion channels. It does not produce intoxicating effects, but its presence opens up interesting questions that researchers are still looking into, especially in areas related to brain function and behaviour.
In developing cannabis-based products, I have noticed a gradual and meaningful shift. There has been growing recognition that a broader cannabinoid profile can add valuable context. More professionals are starting to treat compounds such as CBDV not as background elements, but as important contributors to the overall picture.
I think this change is valuable. Giving proper attention to less familiar cannabinoids such as CBDV brings a fresh perspective. It supports more mindful practices and a fuller appreciation of the cannabis plant.
Frequently asked questions
What is CBDV (cannabidivarin)?
CBDV, or cannabidivarin, is a non-intoxicating cannabinoid naturally occurring in certain cannabis and hemp varieties. It belongs to the same molecular family as CBD (cannabidiol) and is a homologue of it with a shorter side chain.
How does CBDV differ from CBD and THC?
CBDV differs chemically from CBD and THC by having a propyl (three-carbon) side chain instead of a pentyl (five-carbon) chain. This structural variation influences its interaction with receptors and its non-intoxicating properties.
Where does CBDV come from?
CBDV is found primarily in cannabis strains with a higher concentration of CBD, particularly in landrace varieties originating from Asia and Africa. It is naturally synthesised by the cannabis plant during its growth cycle.
Can CBDV get you high?
CBDV does not produce psychoactive effects and is considered non-intoxicating. Unlike THC, it does not activate the CB1 receptor in the brain in a way that alters perception.
How does CBDV compare to CBD and THC?
CBDV shares a similar molecular framework with CBD but differs in its chemical structure. Unlike THC, current research does not associate CBDV with cognitive or euphoric effects.
How is CBDV biosynthesised in cannabis?
CBDV is biosynthesised through the same cannabinoid pathway as CBD, but it begins with divarinolic acid instead of olivetolic acid. The pathway leads to the formation of cannabidivarinic acid (CBDVA), which decarboxylates into CBDV.
Which cannabis strains contain higher levels of CBDV?
Higher CBDV levels have mainly been reported in landrace strains with relatively high CBD and low THC levels, and propyl cannabinoids are especially common in landraces from South Asia and Africa. Published laboratory data confirming high CBDV levels in specific named cultivars, such as "Erdpurt" or "CBD Therapy", are limited.
What is the difference between CBDV and THCV?
Both CBDV and THCV have a propyl side chain, but they act differently at cannabinoid receptors. In experimental studies, THCV has behaved as a CB1 receptor antagonist or, at higher doses, as an agonist, whereas CBDV has low binding affinity for both CB1 and CB2 receptors.
How are cannabis and hemp tested for THC levels?
